Karleen Oberton - Hologic Insider

HOLX -- USA Stock  

USD 41.22  1.09  2.72%

  CFO
Ms. Karleen Marie Oberton is Chief Financial Officer of the Company. Ms. Oberton joined Hologic in 2006 as Corporationrationrate Controller, and was promoted to Corporationrationrate Vice President, Finance and Accounting and Chief Accounting Officer in 2015. In this role, she was responsible for the global finance organization, including controllership functions, financial planning and analysis, and shared services. Before joining Hologic, Ms. Oberton served as Senior Corporationrationrate Controller of Immunogen from 2004 to 2006. Prior to that, she was a Senior Audit Manager in Ernst Youngs Life Science practice and in Arthur Andersens High Technology practice. Ms. Oberton was an active Certified Public Accountant for more than 18 years. She holds a BS in Business Administration from Ms. Oberton joined Hologic in 2006 as Corporationrationrate Controller, and was promoted to Corporationrationrate Vice President, Finance and Accounting and Chief Accounting Officer in 2015. In this role, she was responsible for the global finance organization, including controllership functions, financial planning and analysis, and shared services. Before joining Hologic, Ms. Oberton served as Senior Corporationrationrate Controller of Immunogen from 2004 to 2006. Prior to that, she was a Senior Audit Manager in Ernst Youngs Life Science practice and in Arthur Andersens High Technology practice
  CFO Since 2018      
508-263-2900  http://www.hologic.com
Oberton was an active Certified Public Accountant for more than 18 years. She holds a BS in Business Administration from Merrimack College. .

Karleen Oberton Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 4.59 % which means that it generated profit of $4.59 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (2.98) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 3.27 B in liabilities with Debt to Equity (D/E) ratio of 133.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Hologic has Current Ratio of 1.26 suggesting that it is not liquid enough and may have problems to pay out its financial obligations when they are due.

Similar Executives

Found 14 records

CFO Since

John GlennEkso Bionics Holdings
2018
Maximilian SchederBieschinEkso Bionics Holdings
2014
Robert MichelDaxor Corporation
2018
Vaseem MahboobEndologix
2015
James SaccaroBaxter International
2017
Christopher LindopHaemonetics Corporation
2013
Gregory MatzThe Cooper Companies
2014
Robert HombachBaxter International
2011
Patricia FongCantel Medical Corp
2015
Glenn VraniakElectrocore
N/A
Eric ColemanDaxor Corporation
2016
Jay EwersBovie Medical Corporation
2015
William BurkeHaemonetics Corporation
2016
Christopher ReidyBecton Dickinson and Company
2013

Entity Summary

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts. Hologic operates under Medical Instruments Supplies classification in USA and is traded on BATS Exchange. It employs 6233 people.Hologic (HOLX) is traded on BATS Exchange in USA. It is located in Massachusetts U.S.A and employs 6,233 people. Hologic is listed under Medical Equipment category by Fama And French industry classification.

Hologic Leadership Team

Wayne Wilson, Independent Director
Namal Nawana, Director
Sally Crawford, Independent Director
Jay Stein, Co-Founder, Chairman Emeritus, Chief Technical Officer and Sr. VP
Stephen MacMillan, Chairman, CEO and Pres
Sanjay Prabhakaran, Regional President - Asia
Claus Egstrand, Senior Vice President General Manager - International
Samuel Merksamer, Independent Director
Christiana Stamoulis, Director and Member of Corporate Devel. Committee
Robert McMahon, CFO
Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
Karleen Oberton, CFO, Chief Accounting Officer
Thomas West, Division President of Diagnostics Solutions
Eric Compton, COO
Lawrence Levy, Independent Director
Benjamin Cohn, Principal Chief Accounting Officer
Elaine Ullian, Independent Director
Amy Wendell, Director
Scott Garrett, Independent Director
Peter Valenti, Division President- Breast and Skeletal Health
Nancy Leaming, Independent Director
John Griffin, General Counsel
Allison Bebo, Senior Vice President - Human Resources
Charles Dockendorff, Director
Michael Watts, Vice President IR Contact Officer
Jonathan Christodoro, Independent Director
Al Kildani, Senior Director - Investor Relations

Stock Performance Indicators

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Commodity Channel Index

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Search macroaxis.com